Two billion people around the world have no access to medicine. We believe that pharmaceutical companies have an important role to play in addressing the access to medicine issue and that this particular issue is potentially material to long-term shareholder value creation.

In order to promote better business practices in this area we work with the Access to Medicine Index.

Action is required

The Access to Medicine Index analyses the top 20 research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries. It highlights best and innovative practices, and areas where progress has been made and where action is still required.

In the latest assessment from the Access to Medicine Index (of November 2016) you can see both the overall ranking and company sub-rankings with a more detailed overview of company performance. You can learn about key findings and read a current report on how the industry performs.